Stratistics MRC에 따르면 세계의 용련균 감염증 치료 시장은 2025년에 22억 6,000만 달러를 차지하고, 예측 기간 동안 CAGR 8.0%로 성장해, 2032년에는 38억 8,000만 달러에 달할 것으로 예측되고 있습니다.
용련균 감염증 치료에는 감염을 일으키는 화농 용련균을 제거하기 위한 항생제의 사용이 주로 포함됩니다. 증상의 중증도와 기간을 줄이고, 류마티스 열과 같은 합병증을 피하고, 다른 사람에게 감염시킬 가능성을 줄일 수 있습니다. 이는 휴식, 수분 공급, 아세트 아미노펜 및 이부프로펜과 같은 시중에서 판매되는 진통제를 포함합니다.
미국 질병 관리 예방 센터(CDC)에 따르면, A군 용혈성 연쇄상구균(GAS) 인두염에 대한 항생제 치료는 증상의 지속 기간을 단축하고 합병증을 예방하고 감염을 제한하는 데 필수적입니다.
증가하는 용련균 감염의 유행
A군 용혈성 용련균 또는 GAS로도 알려진 화농용련균은 주로 5-15세의 소아가 앓는 일반적인 세균 감염증인 용연균 감염증의 원인균입니다. 헬스케어에의 액세스가 제한될 가능성이 있는 중저소득국가에서는 그 부담은 세계적으로 한층 더 커집니다.
항생제의 과도한 처방과 잘못된 진단
용련균 감염증 치료 시장의 큰 장벽은 인두통의 일반적인 오진입니다. CDC에 따르면 미국 외래에서는 항생제 처방의 최대 30%가 불필요하다고 합니다.
가정용 신속 진단제 개발
신속 및 가정용 용균 감염 진단 키트의 개발은 자기 검사와 진료의 분산화의 움직임에 촉진되고 있습니다. 또한 이러한 개발은 조기 발견과 치료를 촉진하고, 특히 격리된 장소나 자원이 부족한 장소에서의 임상 인프라에 대한 부담을 줄일 수 있습니다.
제네릭 의약품 경쟁 및 시장 포화 상태
용련균 감염증 치료에는 수십년동안 사용되어 온 소수의 유명한 항생제가 시장을 독점하고 있습니다. 격렬한 가격경쟁과 좁은 이폭이 생겨 이 분야에 대한 의약품 투자나 기술 혁신이 억제되고 있습니다. 또한 독특한 제품이 없기 때문에 시장의 확대가 방해되어 일괄 구입 계약이나 공적기관의 입찰에의 의존도가 높아져, 반드시 채산이 맞는 것은 아닙니다.
COVID-19의 대유행은 용련균 감염증 치료제 시장에 영향을 주었습니다. 한편으로는 마스크의 착용, 사회와의 거리의 취해, 위생 상태의 개선 등의 예방책이 널리 채용된 결과, 용연균 감염증이나 기타 일반적인 호흡기 감염증은 상당히 적어졌습니다. 또한, 감염증이나 항균약 스튜어드십에 대한 일반 시민의 의식의 높아가 가져온 처방 관행이나 헬스케어를 요구하는 행동의 변화에 의해 용연균 감염증의 관리 및 치료법도 시대와 함께 변화하고 있습니다.
예측 기간 동안 경구 부문이 최대가 될 것으로 예상
예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상되는 것은 경구제 부문입니다. 정제, 캡슐제, 현탁제 등의 경구제는 널리 입수 가능하고, 의료 전문가의 감독도 필요 없기 때문에 자원이 한정되어 있는 환경에서도 사용할 수 있습니다. 또한, 연쇄구균성 인두염의 치료제의 세계에서는 널리 입수 가능합니다.
예측기간 동안 급성용연균 감염증 분야가 가장 높은 CAGR이 예상된다.
예측 기간 동안 급성 용련균 감염증 분야가 가장 높은 성장률을 보일 것으로 예측됩니다. 류마티스열이나 용연균 감염 후 사구체 신염 등의 합병증을 회피하기 위해, 의료 종사자는 급성 증례를 우선적으로 치료하게 되어 있어 치료의 필요성이 높아지고 있습니다.
예측 기간 동안 북미가 가장 큰 시장 점유율을 차지할 것으로 예측됩니다. 시장의 확대는 정기적인 건강 진단, 항생제 스튜어드십, 조기 진단을 중시하는 제도와 정부에 의해 더욱 지원되고 있습니다.
예측 기간 동안 아시아태평양이 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 나이가 들수록 증가 경향이 있습니다. 1차 의료를 개선하기위한 정부의 이니셔티브와 항생제에 대한 접근성 향상, 농촌 지역의 의료 지원 활동의 결과로 시장이 확대되고 있습니다.
According to Stratistics MRC, the Global Strep Throat Treatment Market is accounted for $2.26 billion in 2025 and is expected to reach $3.88 billion by 2032 growing at a CAGR of 8.0% during the forecast period. Strep throat treatment primarily involves the use of antibiotics to eliminate the Streptococcus pyogenes bacteria responsible for the infection. Commonly prescribed antibiotics include amoxicillin or penicillin, but patients with allergies may also be treated with cephalexin or azithromycin. The severity and duration of symptoms can be lessened, complications like rheumatic fever can be avoided, and the chance of infecting others is decreased with early antibiotic treatment. Moreover, supportive care can help manage symptoms like fever, inflammation, and sore throat. It includes rest, hydration, and over-the-counter pain relievers like acetaminophen or ibuprofen.
According to the Centers for Disease Control and Prevention (CDC), antibiotic treatment for group A streptococcal (GAS) pharyngitis is essential to reduce symptom duration, prevent complications, and limit transmission. Penicillin or amoxicillin is the recommended first-line therapy due to their efficacy, narrow spectrum, and low cost.
Growing streptococcal infection prevalence
Streptococcus pyogenes, also known as Group A Streptococcus or GAS, is the causative agent of strep throat, a common bacterial infection that primarily affects children between the ages of 5 and 15. The CDC estimates that millions of mild cases, such as strep throat, and between 11,000 and 24,000 cases of invasive GAS disease occur each year in the United States. In low- and middle-income nations where access to healthcare may be restricted, the burden is even greater globally. Additionally, the market for supportive therapies, diagnostics, and antibiotics is constantly active due to this enduring prevalence.
Over prescription and incorrect diagnosis of antibiotics
A major barrier to the market for strep throat treatments is the common misdiagnosis of sore throats. Antibiotics are often prescribed without adequate testing, even though many sore throats are viral rather than bacterial. The effectiveness of treatment is compromised because this not only results in needless drug use but also fuels antibiotic resistance. In outpatient settings in the United States, up to 30% of antibiotic prescriptions are unnecessary, according to the CDC. Furthermore, regulatory pressure and tighter prescription guidelines brought about by this over prescription can indirectly stifle market expansion by reducing the sale of indiscriminate antibiotics.
Developments in at-home and quick diagnostics
The development of quick and at-home strep throat diagnostic kits has been prompted by the move toward self-testing and decentralization of care. Similar to home COVID-19 or pregnancy tests, consumers can now self-test for streptococcal infections using over-the-counter kits owing to developments in digital health and molecular diagnostics. Moreover, these developments facilitate early detection and treatment and lessen the strain on clinical infrastructure, particularly in isolated or resource-constrained locations. Businesses can take advantage of this expanding consumer-driven market by investing in diagnostic solutions that are easy to use, precise, and reasonably priced.
Generic competition and market saturation
A small number of well-known antibiotics that have been used for decades dominate the market for strep throat treatments. There are inexpensive generic versions of many of these medications, including amoxicillin and penicillin. This deters significant pharmaceutical investment and innovation in this field by resulting in fierce price competition and narrow profit margins. Additionally, lack of unique products can impede market expansion and increase reliance on bulk purchasing agreements or public-sector tenders, which aren't always profitable.
The COVID-19 pandemic affected the market for strep throat treatments. On the one hand, strep throat and other common respiratory infections have become much less common as a result of the widespread adoption of preventive measures like mask wearing, social distancing, and better hygiene. The pandemic, however, hastened the uptake of telemedicine and at-home diagnostic instruments, opening up new avenues for the diagnosis and prescription of strep throat remedies. Furthermore, the management and treatment of strep throat has also changed over time as a result of changes in prescribing practices and healthcare-seeking behaviour brought about by heightened public awareness of infectious diseases and antimicrobial stewardship.
The oral segment is expected to be the largest during the forecast period
The oral segment is expected to account for the largest market share during the forecast period. Due to their demonstrated effectiveness, simplicity of use, affordability, and high patient compliance, oral antibiotics-especially penicillin and amoxicillin-are the first-line treatment for strep throat. When it comes to outpatient treatment, the majority of patients-adults and children alike-prefer oral medications over inject able or topical ones. Since oral dosage forms like tablets, capsules, and suspensions are widely accessible and don't need a medical professional's supervision, they can be used even in environments with limited resources. Moreover, their widespread availability and ease of use help explain why they are so popular in the world of strep throat remedies.
The acute strep throat segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the acute strep throat segment is predicted to witness the highest growth rate. The rising incidence of Group A Streptococcus infections worldwide, especially in children and adolescents who are most susceptible to acute strep throat, is what is driving this segment's growth. The expansion of point-of-care testing and growing knowledge of early diagnosis and appropriate antibiotic treatment facilitate quicker acute infection detection and management. Additionally, in order to avoid complications like rheumatic fever and post-streptococcal glomerulonephritis, medical professionals are giving priority to acute cases, which raises the need for treatment.
During the forecast period, the North America region is expected to hold the largest market share, driven by a strong healthcare system, a high level of infectious disease awareness, and easy access to services for diagnosis and treatment. The high incidence of strep throat in the area, particularly in school-age children, contributes to the ongoing need for quick diagnostic tests and antibiotics. Market expansion is further supported by a strong institutional and governmental emphasis on routine health examinations, antibiotic stewardship, and early diagnosis. Furthermore, the availability and innovation of treatments are improved by the presence of top pharmaceutical companies and continuous research and development.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of its sizable and expanding population, increased knowledge of infectious diseases, and easier access to medical care. Strep throat and other respiratory tract infections are on the rise in countries like China, India, and Southeast Asia, especially in young people and the elderly. The market is expanding as a result of government efforts to improve primary healthcare, as well as increased access to antibiotics and healthcare outreach in rural areas. Additionally, the region's market is expanding quickly due to rising investments in telehealth, diagnostic infrastructure, and public health initiatives.
Key players in the market
Some of the key players in Strep Throat Treatment Market include Bayer AG, GSK plc (GlaxoSmithKline), Abbott Laboratories, Merck & Co., Inc., Pfizer Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd, Melinta Therapeutics, Dr. Reddy's Laboratories Ltd., Azurity Pharmaceuticals, Inc., Mylan N.V. (Viatris), Sandoz, Cipla Ltd. and Sun Pharmaceutical Industries Ltd.
In March 2025, Bayer and Suzhou Puhe BioPharma Co.,Ltd announced that they have entered into a global license agreement for Puhe BioPharma's oral, small molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors. Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor.
In March 2025, Merck and Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China. Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.
In December 2024, Abbott Laboratories and DexCom they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices. The agreement will dismiss all pending cases in courts and patent offices worldwide, along with a provision preventing legal action between the companies for patent and appearance disputes for the next 10 years.